#SFHS2608202VNotice on the Decision of the National Union of Health Insurance Funds Regarding the Insured's Rate of Participation for Pharmaceutical Specialties
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This law sets the insured's rate of participation at 35% for a specific pharmaceutical product, Pegzilarginase, provided by IMMEDICA PHARMA FRANCE. This change directly affects insured individuals who require this medication under French health insurance.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Sets insured's rate of participation at 35% for Pegzilarginase
Obligations
What this law requires
Apply a 35% insured participation rate for LOARGYS (pegzilarginase) 5mg/ml solution injectable/pour perfusion en flacon de 0,4 ml (CIP code 34009302832 8) manufactured by IMMEDICA PHARMA FRANCE SARL
Implement this 35% participation rate decision effective from the date of the director general's decision (20 juin 2024)
Communicate the 35% participation rate change to insured individuals requiring LOARGYS medication to inform them of their cost responsibility